SCHEMBL1775472

SCHEMBL1775472

CC(C)(C)OC(=O)N1CCCN(c2nccc3sc(Sc4ccc(Br)cc4)cc23)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.41
KIT P10721 2/20 0.40
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
MET P08581 1/20 0.38
BACE1 P56817 2/20 0.37
GRIA1 P42261 1/20 0.36
GBA1 P04062 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ACHE P22303 2/20 0.35
MKNK1 Q9BUB5 1/20 0.35
ATR Q13535 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
ESRRB O95718 1/20 0.35
ESR1 P03372 1/20 0.35
ESRRA P11474 1/20 0.35
ESRRG P62508 1/20 0.35
DDB1 Q16531 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1776248 0.88 KIT (0.50) PDE10AKITCKS1BSKP1SKP2
SCHEMBL1774703 0.87 KIT (0.42) KITGRIA1GBA1GPR119
SCHEMBL1775680 0.85 PDE10A (0.46) PDE10AKITCKS1BSKP1SKP2
SCHEMBL1775095 0.82 KIT (0.43) PDE10AKITGBA1ACHEMKNK1
SCHEMBL1775118 0.81 KIT (0.48) KITCKS1BSKP1SKP2GRIA1
SCHEMBL12601535 0.78 PDE10A (0.51) PDE10AKITCKS1BSKP1SKP2
SCHEMBL12601538 0.77 PDE10A (0.51) PDE10AKITCKS1BSKP1SKP2
SCHEMBL12601536 0.74 BACE1 (0.51) PDE10AKITCKS1BSKP1SKP2
SCHEMBL12601534 0.73 KIT (0.52) PDE10AKITCKS1BSKP1SKP2
SCHEMBL1775580 0.72 CNR1 (0.45) PDE10AKITCKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943639-B2 Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss PROXIMAGEN LIMITED (GB) 2011-05-17 US disclosed
EP-1897881-A2 Compounds useful for the treatment of obesity, type II diabetes and CNS disorders Biovitrum AB (publ) (SE) 2008-03-12 EP disclosed
EP-1513828-A1 NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS Biovitrum AB (SE) 2005-03-16 EP disclosed
US-20040024210-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2004-02-05 US disclosed
WO-2004000828-A1 NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS BIOVITRUM AB (SE) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024210-A1 New compounds SULT1E1, SULT2A1, SULT1A1 PDE10A 1262/4885KIT 4787/4885CKS1B 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.